"We believe the right way to build value in Curasight is by accelerating our therapeutic strategy so that we develop our cutting-edge radiopharmaceutical platforms uTRACE^® and uTREAT^®, in parallel. We are disappointed that participation in the Rights Issue was less than optimal and we are currently evaluating alternative financing options in order to secure the Company a robust balance sheet to both continue our development activities and ensure we are in a strong position when negotiating potential partnerships." said chairman of the Board of Directors Per Falholt." Together with my colleagues on the board and the executive management team, I would like to take this opportunity to thank the many shareholders who had decided to participate in the Rights Issue and thereby shown their support for our goal to provide improved diagnosis and more gentle treatments for cancer patients. We are committed to finding alternative financing for the Company in order to reward your confidence in our strategy and future growth."

Consequence of the cancellation of the Rights Issue

With reference to section 19.10 of the Information Memorandum published on 22 February 2024, the consequence of the cancellation of the Rights Issue is that:

1. Investors who have submitted subscription commitments will receive back the subscription amount excluding expenses to e.g. the bank or financial intermediaries.
2. For investors who have traded temporary shares, the subscription amounts less expenses will go to the last registered owner of the temporary share.
3. Purchasers of subscription rights will not be compensated for the purchase of subscription rights and they will only receive a subscription amount back ex. Expenses, if they have submitted a subscription commitment.

Shares and share capital

The Company’s share capital will remain unchanged amounting to DKK 994,694.55 and a total number of 19,893,891 shares.

Status

Curasight’s current development activities, including the recently announced Phase I/IIa therapeutic study investigating uTREAT^® in five different cancer types, are funded until 2H 2024. The Company will update the market on alternative financing options in the coming time.

Advisors

Redeye AB is acting as a financial advisor to Curasight. DLA Piper Denmark Advokatpartnerselskab is acting as the legal adviser of Curasight. VP Euronext Securities A/S is the Company’s issuing agent and Nordic Issuing is acting as the settlement agent.

This disclosure contains information that Curasight is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-03-2024 21:53 CET.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com